Table 1.
Control | Moderate | Severe | ||
---|---|---|---|---|
HR | Baseline | 142 ± 6 | 164 ± 9 | 177 ± 9* |
Post Tx | 145 ± 7 | 192 ± 18 | 227 ± 26* | |
Stable | 150 ± 5 | 205 ± 13 | 236 ± 21** | |
MBP | Baseline | 80.8 ± 3.4 | 69.5 ± 4.4 | 84.5 ± 5.6 |
Post Tx | 78.3 ± 2.1 | 68.4 ± 4.8 | 64.7 ± 7.2 | |
Stable | 75.2 ± 3.9 | 68.8 ± 6.5 | 53.4 ± 5.6* | |
CVP | Baseline | 8.8 ± 0.2 | 10.0 ± 1.1 | 8.2 ± 0.4 |
Post Tx | 8.8 ± 0.2 | 10.2 ± 1.5 | 7.0 ± 1.1 | |
Stable | 9.0 ± 0.58 | 9.0 ± 0.84 | 8.0 ± 0.71 |
Note: Heart rate (HR, bpm), mean blood pressure (MBP, mm Hg), and central venous pressure (CVP) measured at baseline, 1 h posttreatment and at the stabilized timepoint at end of study, represented as mean ± SE for each group (N = 5).
P < .05;
P < .01 compared with the control group.